Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Dermatomyositis

• A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
• Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
• Add-on Intravenous Immunoglobulins in Early Myositis
• A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis
• A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)
• Study of M5049 in DM and PM Participants (NEPTUNIA)
• Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)
• Interleukin-2 on Refractory Dermatomyositis
• Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis
• A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
• Efficacy and Safety of Triple Therapy in Patients With Anti-MDA5 Antibody-positive Dermatomyositis
• Baricitinib for Cutaneous Dermatomyositis
• An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
• Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
• Baricitinib in Patients With Relapsing or naïve Dermatomyositis
• The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients
• An Exploratory Study on the Efficacy and Safety of Abatacept in the Treatment of Refractory Dermatomyositis
• Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)
• Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)
• A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis
• A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
• Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)
• A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
• Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
• Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis
• Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study
• Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis
• Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis
• Basiliximab Treating Interstitial Pneumonia of CADM
• A Study In Adults With Moderate To Severe Dermatomyositis
• Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis
• Study of Tofacitinib in Refractory Dermatomyositis
• Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy
• Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis
• Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)
• Trial of IMO-8400 in Adult Patients With Dermatomyositis
• Abatacept in Juvenile Dermatomyositis
• Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
• Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders
• Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study
• Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
• A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia
• Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
• Safety and Efficacy of BAF312 in Dermatomyositis
• Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
• Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis
• Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
• Dermatomyositis and Polymyositis Registry
• Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis
• Abatacept Treatment in Polymyositis and Dermatomyositis
• Anakinra in Myositis
• Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
• A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis
• Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease
• Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM
• Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus
• Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)
• Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis
• A Pilot Study of Etanercept in Dermatomyositis
• Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
• Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis
• Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis
• Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
• Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
• Methimazole to Treat Polymyositis and Dermatomyositis
• Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies